#lly

Eli Lilly agreed to acquire AtaiBeckley for $6.75 a share in cash, valuing the upfront consideration at about $2.8B. A CVR could add up to $2.50 a share, or about $1.0B, tied to BPL-003 and VLS-01 milestones.

Eli Lilly $LLY moved higher after reports that the company plans nearly $4B of vaccine acquisitions. The planned deals clear the Tier-1 M&A threshold and extend Lilly’s GLP-1 cash flow into infectious-disease assets.

$LLY rose more than 10% after Eli Lilly posted Q1 revenue of $19.8 billion, adjusted EPS of $8.55, and lifted its 2026 sales outlook by $2 billion.